ICCC Stock - ImmuCell Corporation
Unlock GoAI Insights for ICCC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $26.49M | $17.47M | $18.57M | $19.24M | $15.34M |
| Gross Profit | $7.94M | $4.40M | $7.65M | $8.66M | $6.86M |
| Gross Margin | 30.0% | 25.2% | 41.2% | 45.0% | 44.7% |
| Operating Income | $-1,640,159 | $-5,748,078 | $-2,299,000 | $257,385 | $-1,380,000 |
| Net Income | $-2,156,629 | $-5,774,598 | $-2,494,000 | $-78,292 | $-1,022,000 |
| Net Margin | -8.1% | -33.1% | -13.4% | -0.4% | -6.7% |
| EPS | $-0.26 | $-0.75 | $-0.32 | $-0.01 | $-0.14 |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Visit WebsiteEarnings History & Surprises
ICCCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.02 | — | — |
Q3 2025 | Aug 14, 2025 | — | $0.06 | — | — |
Q2 2025 | May 14, 2025 | — | $0.16 | — | — |
Q1 2025 | Feb 25, 2025 | — | $0.06 | — | — |
Q4 2024 | Nov 13, 2024 | — | $-0.09 | — | — |
Q3 2024 | Aug 13, 2024 | — | $-0.20 | — | — |
Q2 2024 | May 14, 2024 | — | $-0.06 | — | — |
Q1 2024 | Feb 27, 2024 | — | $-0.15 | — | — |
Q4 2023 | Nov 13, 2023 | — | $-0.12 | — | — |
Q3 2023 | Aug 10, 2023 | — | $-0.18 | — | — |
Q2 2023 | May 11, 2023 | — | $-0.30 | — | — |
Q1 2023 | Feb 21, 2023 | — | $-0.22 | — | — |
Q4 2022 | Nov 21, 2022 | — | $-0.08 | — | — |
Q3 2022 | Aug 11, 2022 | — | $-0.09 | — | — |
Q2 2022 | May 12, 2022 | — | $0.09 | — | — |
Q1 2022 | Feb 22, 2022 | $-0.01 | $0.01 | +200.0% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.06 | $0.02 | +133.3% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.08 | $0.02 | +125.0% | ✓ BEAT |
Latest News
ImmuCell Q3 EPS $(0.02) Up From $(0.09) YoY, Sales $5.506M Down From $6.012M YoY
➖ NeutralImmuCell Names Olivier te Boekhorst As President And CEO, Effective November 1, 2025,
➖ NeutralImmuCell Announces Preliminary Q3 2025 Revenue Of $5.5M
➖ NeutralImmuCell Selects Olivier Te Boekhorst As Its Next President, CEO, Expected Start Date November 1, 2025
➖ NeutralImmuCell Q2 Profit Jumps as Margins Rise
📈 PositiveImmuCell Posts 18% Gain in Q2
📈 PositiveFrequently Asked Questions about ICCC
What is ICCC's current stock price?
What is the analyst price target for ICCC?
What sector is ImmuCell Corporation in?
What is ICCC's market cap?
Does ICCC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ICCC for comparison